We change paradigms.


2004: the research phase begins
2014: the first ECHOPULSE®, treating thyroid nodules and breast fibroadenoma, is delivered
2017: start of the collaboration with the University of Virginia Cancer Center (US) in breast cancer research
2019: SONOVEIN®, our first varicose veins robotic platform, is launched
2022: SONOVEIN HD is launched
2024: SONOVEIN is present in more than 15 countries (Europe, China, USA)


Surgery as we know it carries significant burden for patients as it involves cutting, anesthesia, and long recovery and healing processes converting optimistic patients into anxious individuals. It stretches healthcare systems to the limits of financial and human costs. It can turn brilliant doctors into exhausted system executors, operating under constant extrinsic pressures, from delivering return of investment for expensive infrastructures to managing litigation.



We reduce peri-operative complications and improve healtheconomics. At the core of this mission is echotherapy, coupling high-intensity focused ultrasound (HIFU), detailed ultrasound medical imaging, and advanced data learning. For practitioners, this provides high-level handling precision, and unsurpassed ease of use. For patients, it provides a treatment from outside the body, leaves no scars and allows them to resume their daily activities right after the treatment.

SONOVEIN HD de Theraclion

We lead innovation by extensive clinical research and harnessing artificial intelligence. Currently, phase 2 investigations are underway in the United States for patients with breast cancer by combining Theraclion’s platform with immunotherapy. More importantly, we built a platform which allows our technology to be self-learning. AI is already omnipresent in diagnostics. We lead by bringing it into the treatment arena. No physician can know the best practice cases of all treatments ever performed. Technology can.


Theraclion is changing the paradigm.
Theraclion has made extracorporeal surgery a reality and we live
and breathe to make it accessible to all patients.

Stay tuned!

Our team
Our passionate and committed team of researchers, engineers, and physicians is united by one common goal: leading innovation to change the paradigm by evolving surgery day by day.
Theraclion management
Martin Deterre Chief Executive Officer
Ling Ling Chea, CFO Theraclion Ling Ling Chea Chief Financial Officer
Michel Nuta, Chief Medical Officer at Theraclion Michel Nuta VP Veins & Chief Medical Officer
Jérémie Anquez, Chief Scientific Officer at Theraclion Jérémie Anquez VP Research & Chief Scientific Officer
Gaylord Tallec VP Operations
Vivien Jourdannaud Theraclion Vivien Jourdannaud VP Regulatory Affairs
Marie Berne - Head of Marketing & Customer Relations - Theraclion Marie Berne Marketing & Customer Relations Director
Yann Duchesne Yann Duchesne Chairman of the Board
ari-s-kellen Ari S. Kellen Member of the Board
shawn-langer Shawn Langer Member of the Board
Renaud Saleur Member of the Board
Cédric Bellanger Member of the board
Claude Lenoir Member of the board
Mehdi El Glaoui Member of the Board
Lijuan Deng Member of the board
Xin Lin Member of the board
Filter by

Contact us

244 av. Pierre Brossolette | 92240 Malakoff | France Tel. +33 1 55 48 90 70 | Or fill the contact form Contact us